Loading...
If for any reason you believe you received this email in error or if you no longer wish to receive these emails, click here to unsubscribe. "It's never too late to retire early" Image Source: WeBull Analysts are excited that biotech firm Axsome Therapeutics (AXSM) has a slew of drugs in its pipeline that are expected to propel the company's stock higher in 2022 and beyond.
Axsome's therapies in various stages of development include migraine, Alzheimer's disease, agitation, and narcolepsy treatments, among others. But it's the company's progress with a treatment for a major depressive disorder that has Wall Street swooning.
Analysts believe that Axsome's highly promising AXS-05 drug therapy will be approved for sale and marketing in the near future.
Although Axsome is still waiting for the Food and Drug Administration to approve AXS-05 for major depressive disorder, analysts believe it will happen soon. As a result, the Street's consensus recommendation falls just short of Strong Buy.
Eleven analysts rate Axsome as a Strong Buy, one as a Buy, two as Hold, and one as a Sell. The average target price on Wall Street of $86.61 implies a 140 percent upside in 2022 for shares. Are you ready to make a potential fortune in Crypto during the next few months?We're talking about a single crypto breakout event that could make meme stocks seem like small potatoes. Specifically, I’m talking about a crypto trade of the century… The last time I saw a setup like this, I … Walked away with a $55,985 profit – that’s a 138% gain Banked a $32,482 profit on OMG – that’s over a 34% gain Booked a profit of $23,923 – a 56% gain. Got out of NU with a $17,258 profit – an almost 70% gain. Then, on STORJ, we made a $15,946 profit… a 43% gain. But I’m allowing just 100 readers to grab a ticket and join me for this LIVE trading session. Top headlines you shouldn't miss
Is cash your best option amid high prices and market volatility? Source: Motley Fool Both the stock market and the bond market were trading at excessive valuations as 2022 approached. When investments are so expensive, it's difficult to put your hard-earned money on the line, and many investors may be wondering if stashing cash somewhere might be a better option.
The first week of 2022 was not kind to investors, and it may have frightened some of them into increasing their cash reserves. However, cash may not be the best investment in 2022.
Consider this when mulling over your investments. What you need to know about combining retirement accounts with your spouseInflation concerns are beginning to spell trouble for Capitol Hill 10 best stocks to buy on the Nasdaq right now It's never too late to start saving,
Gordon Fox
P.S.
Know someone who'd love the Late Investor? Be sure to send them to this link so they can get signed up: investinglate.com
The Late Investor, 20 N. Orange Avenue, 32801, Orlando, United States You can unsubscribe here any time. |
Loading...
Loading...